Cite

    Asscher, V. et al. (2020). Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study. Alimentary pharmacology & therapeutics. 52 (8), pp. 1366-1376. [Online].